Stay Informed on Key Developments

Investor News and Updates

Bill_Ipad

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

1 - 10of 392 News
1 - 10of 392 News
November 12, 2024
Third quarter of 2024
Bayer: Strategic progress in challenging business environment – Group outlook confirmed in nearly all parameters
READ MORE
October 19, 2024
Not intended for U.S. and UK Media
Long-term efficacy and safety profile of Eylea™ 8 mg with extended dosing intervals in diabetic macular edema confirmed at three years
READ MORE
October 15, 2024
Not intended for U.S. and UK Media
Bayer submits EU marketing authorization application for elinzanetant to treat moderate to severe vasomotor symptoms
READ MORE
October 14, 2024
Not intended for U.S. and UK Media
Bayer submits application for third indication of darolutamide in the EU
READ MORE
September 27, 2024
Not intended for UK Media
BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months
READ MORE
September 26, 2024
Not intended for U.S. and UK Media
Bayer submits application to U.S. FDA for third indication of darolutamide
READ MORE
September 16, 2024
Not intended for U.S. and UK Media – Data from ARANOTE trial presented as a late-breaking oral presentation at the 2024 ESMO Congress:
Darolutamide plus ADT significantly reduced the risk of radiological progression or death compared to placebo plus ADT in patients with mHSPC
READ MORE
September 10, 2024
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer issues 750 million euro hybrid bond
READ MORE
September 10, 2024
Not intended for UK Media – Late-breaking data from Phase III long-term study OASIS 3 presented at 2024 TMS Annual Meeting:
Data from Phase III study OASIS 3 support efficacy and long-term safety of investigational compound elinzanetant in the treatment of moderate to severe vasomotor symptoms associated with menopause
READ MORE
September 10, 2024
Not intended for U.S. and UK Media – Late-breaking data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024
New subgroup analysis from FINEARTS-HF revealed patients with heart failure and a left ventricular ejection fraction of ≥40% receiving finerenone had a reduced risk of new-onset diabetes
READ MORE
1 - 10of 392 News
1 - 10of 392 News
Inform Yourself on Special Topics
Control Weeds Not Farming

Control Weeds, Not Farming

LEARN MORE
Farmers discussing their weed management

Everything You Need to Know About Glyphosate

LEARN MORE
some-bayer-group-headquarters

Managing Glyphosate Litigation

learn more
woman harvesting carrots

Managing and Mitigating PCB Litigation Risk

learn more